Cargando…

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE

Detalles Bibliográficos
Autores principales:	Wellens, Judith, Edmans, Matthew, Obolski, Uri, Marlow, Luke, Brann, Stephanie, Dunachie, Susanna, Eyre, David W., Helmus, Drew, Barnes, Eleanor, Colombel, Jean Frederic, Wong, Serre-Yu, Klenerman, Paul, Lindsay, James O., Thompson, Craig, Satsangi, Jack J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212638/ http://dx.doi.org/10.1016/S0016-5085(22)60657-7

Ejemplares similares

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION)
por: Doherty, Jayne, et al.
Publicado: (2022)

An Antigenic Thrift-Based Approach to Influenza Vaccine Design
por: Bolton, Jai S., et al.
Publicado: (2021)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS
por: Sperger, John, et al.
Publicado: (2021)

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
por: Spiera, Emily, et al.
Publicado: (2022)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy
por: Selim, Rania, et al.
Publicado: (2022)

786 IMPACT OF THE COVID-19 PANDEMIC ON COLORECTAL CANCER INCIDENCE AND DEATH IN THE UNITED STATES
por: Sharaf, Ravi, et al.
Publicado: (2021)

1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
por: Xu, Alexander, et al.
Publicado: (2022)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS
por: Livanos, Alexandra E., et al.
Publicado: (2021)

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease
por: Wellens, Judith, et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022)

1164: METAGENOMIC INTERROGATION OF RESPIRATORY AND GUT MICROBIAL COMMUNITIES, HOST IMMUNE RESPONSE, AND RISK OF SEVERE COVID-19
por: Nguyen, Long H., et al.
Publicado: (2022)

Burnout, Depression, and Borderline Personality: A 1,163-Participant Study
por: Bianchi, Renzo, et al.
Publicado: (2018)

AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
por: Sultan, Shahnaz, et al.
Publicado: (2020)

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
por: Sultan, Shahnaz, et al.
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Su1187 ALMOST EVERYTHING CAUSES DIARRHEA: GASTROINTESTINAL MANIFESTATIONS OF ACUTE RESPIRATORY INFECTIONS AMONG 3,510 INDIVIDUALS IN A COMMUNITY-BASED STUDY
por: Newman, Kira L., et al.
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

Sa101 INCREASING THE LOW-RISK THRESHOLD FOR PATIENTS WITH UPPER GASTROINTESTINAL BLEEDING DURING THE COVID-19 PANDEMIC: A PROSPECTIVE, MULTICENTRE, FEASIBILITY STUDY
por: Dunne, Philip, et al.
Publicado: (2021)

Sa002 IMPACT OF THE COVID-19 PANDEMIC ON A LARGE ORGANIZED COLORECTAL CANCER SCREENING PROGRAM BASED ON FECAL IMMUNOCHEMICAL TESTING AND OPPORTUNISTIC COLONOSCOPY
por: Levin, Theodore R., et al.
Publicado: (2021)

Sa003 COVID-19 PANDEMIC AND REDUCTION OF COLORECTAL CANCER SCREENING RELATED PROCEDURES IN THE CZECH REPUBLIC
por: Suchanek, Stepan, et al.
Publicado: (2021)

Sa004 DECLINING COLORECTAL CANCER SCREENING IN THE AGE OF COVID-19
por: Torres, Jon Alexander, et al.
Publicado: (2021)

Fr089 IMPACT OF COVID-19 ON PANDEMIC MAJOR GASTROENTEROLOGY PROCEDURES, VISITS, AND NEW DIAGNOSIS OF GASTROINTESTINAL CANCERS
por: Khan, Ahmad, et al.
Publicado: (2021)

Sa504 INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN SOUTH ASIAN AND CHINESE PEOPLE: A POPULATION-BASED COHORT STUDY FROM ONTARIO, CANADA
por: Dhaliwal, Jasbir, et al.
Publicado: (2021)

109 THE RISK ASSESSMENT OF NASOGASTRIC INTUBATION, A DAILY CLINICAL PRACTICE, DURING THE COVID-19 THREAT BY AEROSOL GENERATION AND DROPLET SPREAD
por: Verbeure, Wout, et al.
Publicado: (2021)

AGA-Mitteilungen
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_81j6td2bi44ttov5gf81igi2e2